PREVEXXION® RN: the next generation of Marek’s disease vaccines now available in the EU and the UK

Ingelheim, Germany, Tue, 04/13/2021 - 09:00

PREVEXXION^® RN is the results of unprecedented engineering design in vaccinology which brings optimal safety and efficacy balance
The product’s early Marek’s disease onset of immunity from five days of age provides full protection of broilers, layers and breeders against the most virulent Marek’s disease virus strains
It is also fully compatible with VAXXITEK^®HVT+IBD and available in the same ampoule for added convenience

Ingelheim, Germany, April 13, 2021 – Boehringer Ingelheim, a global leader in animal health, is pleased to announce the launch of PREVEXXION^® RN and PREVEXXION^® RN+HVT+IBD, the next generation of Marek’s disease vaccines, in the European Union countries and the United Kingdom.

PREVEXXION® RN is the first innovation¹ in the Marek category in over 40 years. Its purpose is to provide poultry producers with cutting-edge technology in terms of Marek's disease protection. PREVEXXION^® RN range is composed of an innovative serotype-1 construct vaccine with a unique balance between safety and efficacy against the most virulent types of Marek’s disease virus strains.

PREVEXXION^® RN+HVT+IBD is a unique, convenient, and high-performance solution combining PREVEXXION^® RN and VAXXITEK^® HVT+IBD in one ampoule. This 3 in 1 solution is specifically designed to answer our customer needs in long-life bird segments with the most appropriate protection from the hatchery. PREVEXXION^® RN vaccines are available in ampoules of 1000, 2000, and 4000 doses, frozen in liquid nitrogen.

Jerôme Baudon, Head of Poultry at Boehringer Ingelheim, commented: “Our PREVEXXION^® RN range provides value through innovation to Marek sensitive poultry producers looking for continuous live production productivity improvement and effective protection. Field and lab experiments conducted worldwide demonstrated its safety, efficacy and its strong, early, and long-lasting protection through the lifespan of the birds and against very virulent Marek’s disease challenge. PREVEXXION^® RN is the new golden standard for Marek's disease vaccination programs²”.

This PREVEXXION^® launch completes the availability of the PREVEXXION^®RN range worldwide.

To know more about PREVEXXION^® RN range, please contact your Boehringer Ingelheim representative.

Boehringer Ingelheim Animal Health

The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 9,700 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.

Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4.1 billion euros in 2020 and presence in more than 150 countries. For more information visit: www.boehringer-ingelheim.com/animal-health/overview.

Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.